Daxor’s BVA System Validated as Superior to Clinical Scores in Capillary Leak Detection
Event summary
- Daxor’s Blood Volume Analyzer (BVA) demonstrated superior accuracy in detecting capillary leak compared to traditional clinical scores in a study presented at SCCM 2026.
- The study found BVA identified elevated albumin escape rates even when clinical scores remained low, highlighting its mechanistic specificity.
- Daxor positions its BVA system as the only tool capable of directly measuring albumin leak, expanding its potential in critical care and heart failure markets.
- The research was led by Dr. Jonathan Popham from Children’s National Hospital and presented at the SCCM 2026 Critical Care Congress.
The big picture
Daxor’s validation of its BVA system against traditional clinical scores addresses a critical gap in measuring capillary leak, a key driver of organ failure in ICU patients. This positions Daxor as a leader in precision medicine for high-cost medical conditions like heart failure and sepsis. The study’s findings could accelerate adoption of BVA in critical care settings, where accurate fluid imbalance assessment is essential for individualized treatment.
What we're watching
- Market Expansion
- The pace at which Daxor can expand its BVA system into critical care and heart failure markets, leveraging its unique diagnostic capabilities.
- Competitive Positioning
- Whether traditional clinical scores will be validated in inflammatory leak settings or if Daxor’s BVA remains the sole reliable metric.
- Regulatory and Clinical Adoption
- How quickly clinicians and healthcare systems adopt Daxor’s BVA system, given its proven superiority in detecting capillary leak.
Related topics